It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.



TRUST Campaign
eligible patients icon

Eligible patients pay $0 co-pay

Eligible, commercially insured patients can enroll by phone

billing coding icon

Billing and coding for ZARXIO

Payer-specific coding requirements

real world success icon

Proven real-world success with Sandoz

Expanding patient access with biosimilars

flame icon

Learn about our long-acting G-CSF option

Safety profile and proven efficacy you've come to expect5-7

Eligibility Requirements: Maximum benefit of $10,000 annually. Prescription must be for an approved indication. This program is not health insurance. This program is for insured patients only; cash-paying or uninsured patients are not eligible. Patients are not eligible if prescription for ZARXIO is paid, in whole or in part, by any state or federally funded programs, including but not limited to Medicare (including Part D, even in the coverage gap) or Medicaid, Medigap, VA, DOD, or TRICARE, or private indemnity plans that do not cover prescription drugs, or HMO insurance plans that reimburse the patient for the entire cost of their prescription drugs, or where prohibited by law. Co-Pay Program may apply to out-of-pocket expenses that occurred within 120 days prior to the date of the enrollment. Co-Pay Program may not be combined with any other rebate, coupon, or offer. Co-Pay Program has no cash value. Sandoz reserves the right to rescind, revoke, or amend this offer without further notice.

G-CSF=granulocyte colony-stimulating factor.

Neupogen is a registered trademark of Amgen Inc.

References: 1. Data on file. Zarxio Market Share Analysis. Sandoz Inc. September 2020. 2. ZARXIO Prescribing Information. Sandoz Inc. March 2021. 3. FDA approves first biosimilar product Zarxio [press release]. US Food and Drug Administration; March 6, 2015. Accessed January 13, 2020. 4. Data on file. Sandoz Biosimilar PSUR Data. Sandoz Inc. February 2021. 5. ZIEXTENZO Prescribing Information. Sandoz Inc. March 2021. 6. Harbeck N, Lipatov O, Frolova M, et al. Randomized, double-blind study comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer. Future Oncol. 2016;12(11):1359-1367. 7. Blackwell K, Donskih R, Jones MC, et al. A comparison of proposed biosimilar LA-EP2006 and reference pegfilgrastim for the prevention of neutropenia in patients with early-stage breast cancer receiving myelosuppressive adjuvant or neoadjuvant chemotherapy: pegfilgrastim randomized oncology (supportive care) trial to evaluate comparative treatment (PROTECT-2), a phase III, randomized, double-blind trial. Oncologist. 2016;21(7):789-794.